Regulatory Frameworks

Orphan Drug Designation Application Process: Common Pitfalls to Avoid

Posted on digi By digi

The U.S. Food and Drug Administration (FDA) offers Orphan Drug Designation (ODD) to sponsors developing therapies for rare diseases—conditions affecting fewer than 200,000 people in the United States. This designation provides benefits such as 7 years of market exclusivity, tax credits, fee waivers, and FDA regulatory support. However, the application process can be complex, and many sponsors—especially small biotech firms—fall into avoidable traps that delay or jeopardize designation.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Frameworks

Differences Between U.S. and EU Rare Disease Regulatory Pathways

Posted on digi By digi

Rare diseases pose significant challenges in clinical research, including small patient populations, limited natural history data, and high development costs. To encourage innovation, both the United States and European Union offer regulatory incentives through distinct frameworks: the U.S. FDA’s Orphan Drug Act (1983) and the EU Orphan Regulation (EC No 141/2000). While both aim to facilitate development and approval of rare disease therapies, they differ in eligibility criteria, application processes, and post-approval benefits.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Frameworks

Expedited Review Mechanisms for Rare Disease Clinical Trials in Asia-Pacific

Posted on digi By digi

As global pharmaceutical companies expand clinical research into emerging markets, the Asia-Pacific (APAC) region has gained increasing relevance in rare disease trials. Several countries in APAC—including Japan, South Korea, Australia, Singapore, and China—have introduced expedited review mechanisms to facilitate the development and approval of therapies for orphan and ultra-rare conditions. These programs aim to address unmet medical needs by shortening regulatory timelines and improving trial feasibility in diverse populations.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Frameworks

Regulatory Compliance for Cross-Border Rare Disease Studies

Posted on digi By digi

Rare disease trials often require collaboration across multiple countries to achieve adequate patient recruitment. This cross-border approach, while necessary, introduces a host of regulatory challenges—from differing clinical trial application (CTA) processes to varied ethics committee expectations, import/export rules, and safety reporting requirements.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Frameworks

How to Prepare for Regulatory Inspections in Rare Disease Trials

Posted on digi By digi

Rare disease trials often operate under accelerated timelines, smaller patient populations, and unique regulatory incentives like orphan drug designation and priority review. These characteristics increase the likelihood of regulatory inspections from agencies such as the FDA, EMA, MHRA, and PMDA. Ensuring Good Clinical Practice (GCP) compliance in such trials is critical to avoid delays in approval and ensure patient safety.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Frameworks

Combining Orphan Drug and Breakthrough Designations: Opportunities and Challenges

Posted on digi By digi

Rare disease therapies face considerable scientific and logistical challenges due to limited patient populations, fragmented natural history data, and evolving regulatory expectations. Fortunately, the FDA and other global regulators offer specific incentive programs such as Orphan Drug Designation (ODD) and Breakthrough Therapy (BT) to facilitate faster development and review. When used together, these designations can create a powerful framework for expediting approval and maximizing regulatory support.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Frameworks

Regulatory Risk Assessment for Rare Disease Clinical Development

Posted on digi By digi

Rare disease clinical development faces unique regulatory uncertainties due to small patient populations, limited data, and high unmet medical needs. A proactive regulatory risk assessment is essential to identify, prioritize, and mitigate compliance, ethical, and operational risks that may affect approval timelines and trial integrity.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Frameworks

Navigating Compassionate Use Programs from a Regulatory Perspective

Posted on digi By digi

For patients with rare and life-threatening diseases, access to investigational therapies before formal marketing authorization can be life-saving. Compassionate Use—also known as Expanded Access—provides a regulated pathway for patients who are not eligible for clinical trials to receive promising treatments still under investigation.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Frameworks